The predictive value of baseline symptom score and the peripheral CD4CD8 double-positive T cells in patients with AECOPD

Table 5 Effects of lymphocyte subsets on different COPD exacerbation statuses with a 2-year follow-up

Variables	No Exacerbators (N = 53)		Mild Exacerbators (N = 15)		Moderate Exacerbators (N = 7)		Severe Exacerbators (N = 49)		P Value
Variables	N	Value	N	Value	N	Value	N	Value	P Value
T lymphocytes%^b	53	63.7(55.6,72.8)	15	72.0(63.6,78.9)^d	7	71.2(44.2,74.2)	49	70.1(62.3,75.9)^d	0.09
CD4⁺ T cells%^a	53	37.5 ± 11.1	15	43.5 ± 8.5	7	37.1 ± 11.6	49	40.0 ± 10.6	0.23
CD8⁺ T cells%^b	53	23.4(17.5,32.1)	15	26.4(19.9,31.4)	7	19.9(14.5,41.2)	49	25.9(19.2,32.1)	0.90
CD4⁺CD8⁺ T cells%^b	53	0.85(0.56,1.58)	15	1.02(0.53,1.24)	7	0.97(0.17,1.76)	49	0.71(0.38,1.07)	0.22
CD4⁻CD8⁻ T cells%^b	53	1.66(0.43,3.39)	15	2.41(1.35,3.97)	7	1.76(0.71,2.83)	49	1.48(0.66,3.37)	0.65
NK cells%^b	53	24.2(13.4,33.5)	15	12.2(6.1,22.0)^d	7	15.5(11.1,47.5)	49	18.4(10.1,26.3)	0.07
T4/T8 ratio%^b	53	1.62(1.03,2.43)	15	1.71(1.25,2.04)	7	1.92(0.81,2.40)	49	1.59(1.07,2.12)	0.92
B lymphocytes%^b	53	11.6(6.1,16.2)	15	13.0(8.8,16.9)	7	11.5(8.4,15.8)	49	11.4(7.3,17.0)	0.79

COPD chronic obstructive pulmonary disease, NK cells natural killer cells
Data are expressed as
^amean ± SD
^bmedian; 25–75th percentile. P values: One-way ANOVA was used to analyze the normally distributed continuous variables of within-group difference between the COPD exacerbation status. The Kruskal–Wallis test was used for the non-normally distributed variables
^cP < 0.001
^dP < 0.05 for comparison with individuals with COPD but no exacerbation history

ISSN: 1471-2466